Combination drug treatment can cut malaria by 30 percent

April 2, 2012, Walter and Eliza Hall Institute

Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.

The trial showed the drug regime was effective against both Plasmodium falciparum and , the first time have been shown to prevent infections by both species of malaria. The treatment regime, called intermittent preventive treatment (IPT), protected the infants against malaria for at least six weeks after the end of treatment, showing that it had an ongoing protective effect and did not hinder the development of natural immunity.

The study was led by Professor Ivo Mueller from the Walter and Eliza Hall Institute and Barcelona Centre for International Health Research (CRESIB) with Dr Patricia Rarau and Dr Nicolas Senn from the Institute of Medical Research (PNGIMR). Professor Peter Siba from PNGIMR, Associate Professor Louis Schofield from the Walter and Eliza Hall Institute, Professor John Reeder and Dr James Beeson from the Burnet Institute and Professor Stephen Rogerson from the University of Melbourne also collaborated on the project.

Professor Mueller, from the Walter and Eliza Hall Institute's Infection and Immunity division, said the findings could lead to trials of IPT in other regions, including South-East Asia and South America, where malaria, particularly P. vivax, is a major health problem. IPT has been used for number of years in sub-Saharan Africa, where more than 80 per cent of all deaths from malaria are in children under the age of five.

"Plasmodium vivax is the main cause of clinical malaria in infants outside of Africa," Professor Mueller said. "What this study has shown is that IPT can be useful in regions other than sub-Saharan Africa, that it can be an effective tool against P. vivax, and reaffirms that we need to effectively tailor preventive drugs to different malaria species in different regions."

IPT uses sporadic, short courses of combined antimalarial drugs to provide protection against malaria infection. "IPT is a cheap and easy way to decrease the burden of malaria in those most susceptible to clinical illness, such as young infants and pregnant women," Professor Mueller said.

As part of the clinical trial, infants aged three to 15 months were treated with a long-lasting antimalarial drug combination at three, six, nine and 12 months. Professor Mueller said the most effective drug combination in the trial was the long-lasting antimalarials sulfadoxine/pyrimethamine and amodiaquine (SP-AQ), which act against the two most lethal species of malaria parasite, Plasmodium falciparum and Plasmodium vivax. In the trial, SP-AQ treatment decreased infant infections by 35 per cent for and 23 per cent for Plasmodium vivax.

"These are quite remarkable figures," Professor Mueller said. "Different treatment strategies are required for different regions, depending on the dynamics of disease. The that was most effective in PNG was very different to the drugs you would use to treat malaria in Africa and also different to the drugs currently recommended for treating malaria in PNG."

Professor Peter Siba, director of PNGIMR, said a key factor in the effectiveness of the treatment was running it in parallel with existing vaccination and healthcare programs.

"In the trials, IPT was given at the same time as regular vaccinations and check-ups, using existing health care frameworks to deliver the treatment, so we saw a much higher adherence than with continuous treatment regimes. IPT is also preferable to long-term, continued use of antimalarial drugs, as it allows some to develop while decreasing the number and severity of malaria infections," Professor Siba said.

Explore further: Comparing antimalarial drugs and their effects over the Plasmodium lifecycle

Related Stories

Comparing antimalarial drugs and their effects over the Plasmodium lifecycle

February 21, 2012
In this week's PLoS Medicine, Michael Delves of Imperial College London, UK and colleagues compare the activity of 50 current and experimental antimalarials against liver, sexual blood, and mosquito stages of selected human ...

Malaria during pregnancy: New study assesses risks during first trimester

December 13, 2011
The largest ever study to assess the effects of malaria and its treatment in the first trimester of pregnancy has shown that the disease significantly increases the risk of miscarriage, but that treating with antimalarial ...

'Protein microarrays' may reveal new weapons against malaria

November 1, 2011
A new research technology is revealing how humans develop immunity to malaria, and could assist programs aimed at eradicating this parasitic disease.

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.